Ekta Patel

Ekta Patel

Company: Xilio Therapeutics Inc.

Job title: Director - Translational Biomarkers

Seminars:

XTX301, A Half-Life Extended, Tumor-Selective IL-12, Exerts Potent Anti-Tumor Activity in Mice & has the Potential To Widen the Therapeutic Index of IL-12 Treatment. 11:30 am

• mXTX301 potently inhibits tumor growth in a syngeneic mouse model. • XTX301 is well-tolerated in a repeat dose non-GLP non-human primate study. • XTX301 may exert potent anti-tumor activity while widening the potential therapeutic index of IL-12 treatment.Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.